VBIO vs AIXI Comparison

Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.

XIAO-I Corp operates as a cognitive artificial intelligence company. Using its proprietary intellectual property technologies, the company has developed and commercialized various core technologies, such as Conversational AI, Knowledge Fusion, Intelligence Voice, Hyperautomation, Data Intelligence, Cloud, Intelligent Construction Support, Vision Analysis, Intelligent Hardware Support, and Metaverse. Additionally, it has developed Hua Zang Universal Large Language Model. XIAO-I offers two different product lines: Model as a service (MaaS) and non-MaaS. Key revenue is derived from the non-MaaS product line, which comprises needs assessment, solution design and architecture planning, development and configuration, deployment, and implementation of non-model (mainly cloud platform) products.